Switzerland news - the latest biotech news from Labiotech.eu

Home Switzerland Page 20

Latest Posts

pomegranate Nat Med01

News and Trends 18 Jul 2016

Switzerland discovers Pomegranate ‘Anti-Ageing’ Effect and founds Biotech

Researchers at the École Polytechnique Fédérale de Lausanne (EPFL) have uncovered a molecule in the pomegranate fruit which can prolong the lifespan of animal models. The co-authors who published in Nature went to co-found a biotech Amazentis to develop the wonder molecule into clinical trials. There are many underlying factors to what happens to our bodies as we age. However, […]

July 18, 2016 - 3 minutesmins - By Dani Bancroft

cell medica delenex car t

News and Trends 15 Jul 2016

UK Biotech buys Swiss Antibodies to accelerate CAR-T Development

Cell Medica is a London-based biotech which develops, manufactures and markets personalised cell immunotherapeutics for infectious disease and cancer. It has therefore just acquired a Swiss antibody manufacturing biotech Delenex, to help its progress into the CAR-T field. Update 20/07/16: Cell Medica has also just received EMA Orphan Drug Designation for their CMD-003 candidate. This means it can obtain regulatory and […]

July 15, 2016 - 3 minutesmins - By Dani Bancroft

e Dura 2

News and Trends 14 Jul 2016

Sci-fi Spinal Cord Implant could help Paralyzed Patients walk again

Getting up from a wheelchair is a shared dream of paralyzed people all across the world. A dream that might soon become true thanks to a new skin-like implant that directly stimulates the patients’ spinal cord through electric pulses. The sci-fi technology developed by researchers at École Polytechnique Fédérale of Lausanne (EPFL) in Switzerland has […]

July 14, 2016 - 2 minutesmins - By Lourdes Riquelme

actelion insomnia biotech trials pah

News and Trends 13 Jul 2016

Europe’s most valuable Biotech just launched 2 new Trials

Within a week, Actelion has announced both Phase II and III trial studies for insomnia and hypertension in children. Even for Europe’s most valuable biotech, this is an impressive period. Actelion is to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia. The day before this, it also announced a […]

July 13, 2016 - 3 minutesmins - By Dani Bancroft

roche biomarin acquisition biotech

News and Trends 11 Jul 2016

After Genentech, Roche could acquire another American Billion-dollar Biotech

Roche is rumored to make a move on the California biotech BioMarin. Despite a slightly weakened pipeline, Roche appears undeterred and previous offers were predicted to be around $15Bn. As big as some of the other industry veterans, BioMarin was founded in the 90’s boom in Biotech in San Rafaele, California. The deal itself is entirely based on […]

July 11, 2016 - 2 minutesmins - By Dani Bancroft

morphosys thrombosis phaseI novartis hucal

News and Trends 4 Jul 2016

Novartis delivers German Biotech’s 12th Antibody to Clinics

MorphoSys keeps up its impressive productivity in feeding pipelines. Its 12th antibody in its Novartis collaboration has just reached clinical development. After presenting results for two of its wholly-owned candidates at ASCO 2016 (you can get an insider look into ASCO from the team), MorphoSys is receiving good news on the collaborations’ front. One of the […]

July 4, 2016 - 2 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT

crispr therapeutics finance round b

News and Trends 27 Jun 2016

CRISPR Therapeutics increases its Series B to a Massive €125M

Everyone wants to invest in CRISPR Therapeutics, it seems. The Basel and Cambridge, US biotech has raised more money for its ongoing Series B round, bringing the total to over €126M. The authorization for the first CRISPR trials have just arrived in the hands of the FDA, and this might have encouraged new investment. CRISPR Therapeutics […]

June 27, 2016 - 2 minutesmins - By Denise Neves Gameiro

bacteria vaximm immunooncology

News and Trends 20 Jun 2016

Meet the Biotech successfully using Bacteria for Immuno-Oncology

Yes, the title may have surprised you, but it’s true. Vaximm is one of the few biotechs worldwide using bacteria to activate the immune system against cancer. I was really surprised about how elegant the technology is when I had a chat with the Executive Chairman Klaus Breiner at BioEquity in Copenhagen. Vaximm is based in Basel […]

June 20, 2016 - 4 minutesmins - By Philip Hemme

crispr therapeutics muscle stem cells anagenesis

News and Trends 10 Jun 2016

CRISPR Thx in yet another Collaboration, this time for Muscle Dystrophy

CRISPR Therapeutics has struck a deal with Anagenesis Biotechnologies, which has key technology for muscle stem cells. Together, they will tackle muscle disorders – including the rare disease Duchenne Muscular Dystrophy (DMD). CRISPR Therapeutics (Basel, Switzerland) is the European champion of gene editing for health applications, a field that promises to revolutionize therapies – even if […]

June 10, 2016 - 3 minutesmins - By Denise Neves Gameiro

zurich biotech octapharma ehtz switzerland

News and Trends 7 Jun 2016

Zurich is not all about Money – here are 9 Biotechs proving it!

The biggest city in Switzerland, Zurich, is one of Europe’s top financial centers and home to the SIX Swiss Exchange (SWX). It’s also one of the most expensive cities in Europe to live in (as my Swiss colleague Claire could confirm). With so much money nearby, how does the local Biotech ecosystem looks like? The biggest Biotech/mid-size Pharma in […]

June 7, 2016 - 5 minutesmins - By Denise Neves Gameiro

numab intarcia antibodies implantable drug delivery

News and Trends 6 Jun 2016

Swiss-US Implant could make taking pills obsolete in Autoimmune Diseases

Numab and Intarcia have achieved key milestones in the development of therapeutic antibody fragments. This collaboration could span the next generation of implantable drug delivery tech for diabetes, obesity and autoimmune diseases. Based in Wädenswill (near Zurich), Numab is developing antibody-based therapeutics. With its ultra-high throughput technology, it can find rare molecules with big therapeutic potential that are […]

June 6, 2016 - 2 minutesmins - By Denise Neves Gameiro

crispr therapeutics gene editing labiotech refresh philip hemme biotech roger novak

News and Trends 1 Jun 2016

CRISPR Thx’ Founder: “We have over $250M in the bank”

So begins our series of videos documenting our biotech conference premier – Labiotech Refresh. Here Philip spoke with Rodger Novak, the CEO and founder of CRISPR Therapeutics, which is leading the biotech front on Gene Editing in Europe. Having the CEO of CRISPR Therapeutics come and speak at our first event was really exciting for […]

June 1, 2016 - 2 minutesmins - By Dani Bancroft

ADVERTISEMENT